 | |
 | |
| Combination of | |
|---|---|
| Empagliflozin | SGLT2 inhibitor |
| Linagliptin | DPP-4 inhibitor |
| Clinical data | |
| Trade names | Glyxambi |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C48H55ClN8O9 |
| Molar mass | 923.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Empagliflozin/linagliptin, sold under the brand nameGlyxambi, is afixed-dose combinationanti-diabetic medication used to treattype 2 diabetes.[5][6] It is a combination ofempagliflozin andlinagliptin.[5][6] It is takenby mouth.[5][6]
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[5][6]
It was approved for use in the United States in January 2015,[7][8] for use in the European Union in November 2016,[6] and for use in Australia in December 2016.[2]
In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults withtype 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and establishedcardiovascular disease.[5]
In the European Union empagliflozin/linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus:[6]
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[5][6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’),pancreatitis (inflammation of the pancreas),hypersensitivity (allergic reactions) andhypoglycaemia (low blood sugar levels).[6]
The combination preparation was developed and is marketed byBoehringer Ingelheim andEli Lilly and Company under the brand nameGlyxambi.[9]
